Chugai Seiyaku Kabushiki Kaisha

Takeaki Kawai

Tomoyuki Igawa

Shojiro Kadono

Hitoshi Katada

Yuji Hori

Shun Shimizu

Mika Sakurai

Hiroki Kawauchi

Taro Miyazaki

Kanako Tatsumi

Masaki Kamimura

Masami Hasegawa

Akira Hayasaka

Yoshinori Narita

Naoka Hironiwa

Nasa Savory

Futa Mimoto

Takayuki Kamikawa

An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same. Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided. The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.

Anti-CD137 antigen-binding molecule and utilization thereof

The present invention relates to pharmaceutical compositions containing a combination of a first antigen-binding molecule and a second antigen-binding molecule, wherein the first antigen-binding molecule and the second antigen-binding molecule are not linked by a covalent bond, and they are more likely to form a heterodimer than homodimers when mixed in solution. Furthermore, the present invention relates to antigen-binding molecules, therapeutic methods, and screening methods that are associated with the combination.

Compositions comprising antigen-binding molecules

Growing community of inventors

Shizuoka, Japan

Takeaki Kawai